Technical Intelligence & Insights
Explore our curated collection of technical analyses and commercial scale-up strategies specifically focused on R 3 Hydroxybutyrate. These insights are designed to support R&D and procurement teams in optimizing their supply chains.
Novel biocatalytic route for L-carnitine production offers >99% ee, reduced toxicity, and scalable manufacturing for reliable pharmaceutical intermediate supply chains.
Patent CN109943597B reveals enzyme membrane reactor tech for statin intermediates. Offers continuous production and reduced emulsification for supply chain efficiency.
Patent CN114908129B reveals a novel dehydrogenase mutant for high-purity (R)-4-chloro-3-hydroxybutyric acid ethyl ester production, offering significant cost and supply chain advantages.
Patent CN102925501A details a high-efficiency enzymatic route for statin intermediates, offering superior purity and scalable manufacturing capabilities for global supply chains.
Patent CN103420837A reveals a cobalt-catalyzed hydroesterification route for chiral 4-chloro-3-hydroxybutyrate, offering high atom economy and supply chain reliability for pharmaceutical manufacturers.
Novel enzymatic route for 4-AA intermediate reduces costs and improves purity for penem antibiotic manufacturing supply chains globally.
Advanced synthesis of Ethyl (R)-4-Cyano-3-Hydroxybutyrate via epoxide intermediate. High purity >99%, scalable process for Atorvastatin manufacturing.
Patent CN105358687B reveals surface displayed designer cells for efficient chiral alcohol production offering significant supply chain and cost advantages for pharmaceutical manufacturing.
Patent CN106754775B details ScCR1 mutants for Atorvastatin intermediate. Offers high stability and activity for cost-effective manufacturing.
Patent CN101392225B details a recombinant yeast method for high-purity statin intermediates, offering significant cost reduction in API manufacturing and supply chain reliability.
Patent CN101962661B reveals high-efficiency carbonyl reductase for statin intermediates. Offers superior yield and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN103589665A reveals a novel Rhodococcus qingshengii strain for high-purity (S)-CHBE production, offering significant cost reduction in API manufacturing.
Patent CN103420870A details a novel carbonylation route for high-purity chiral 4-cyano-3-hydroxybutyrate, offering significant cost reduction and scalable manufacturing for statin intermediates.
Patent CN111705068A reveals a novel ketoreductase route for high-purity (R)-EHB, offering significant cost reduction and scalability for antibiotic intermediates.
Patent CN111499538A details a novel Ru-C3*-Tunephos catalytic system for high-purity pharmaceutical intermediates, offering significant cost reduction and scalable manufacturing solutions.
Novel Bacillus megaterium strain enables high-purity R-4-chloro-3-hydroxybutyrate production with reduced costs and environmental impact.
Patent CN1778889A details high-purity S-CHBE production via Aureobasidium pullulans. This method offers significant cost reduction and supply chain reliability for global buyers.
Patent CN103589665B reveals Rhodococcus qingshengii strain for high-purity (S)-CHBE production. Offers mild conditions and cost reduction in pharmaceutical intermediate manufacturing.
Patent CN114394892B reveals a high-purity synthesis route for R-3-hydroxybutyrate. This method ensures supply chain stability and significant cost reduction.
Patent CN113652408B reveals mutant enzyme for high-purity intermediate. Offers supply chain reliability and cost reduction in pharmaceutical intermediates manufacturing.